History
of MorphoSys

You are here

MorphoSys was founded in Martinsried near Munich in 1992. The founders included Dr. Simon Moroney, today’s CEO of the Company and Prof. Dr. Andreas Plückthun. Today, MorphoSys is one of the world’s leading biotechnology companies in the area of fully human antibodies.

1992 the beginning

Martinsried bei München.

The company was founded in Martinsried near Munich.

1999 IPO

MorphoSys AG goes public on the Frankfurt Stock Exchange in 1999. On September 6, 2004, the Company entered into the TecDAX and in 2018 to the MDAX.

2000 antibody technology

In 2000, MorphoSys presented its HuCAL antibody library. This was followed by the HuCAL Gold antibody library (2001) and the HuCAL PLATINUM antibody library (2008). Ylanthia, the next generation of antibody technologies, was launched in 2011. Slonomics, which has been part of the MorphoSys technology portfolio since 2010, enables the precise optimization of antibodies from the Ylanthia library.

2004 service and discovery partnerships

Initiation of a strategic partnership with Novartis in 2004, which expands into one of the largest antibody research collaborations in biotech and pharmaceuticals in 2007. MorphoSys has been researching and discovering antibodies on behalf of pharmaceutical partners since 1997. These include further partnerships with Bayer (1999), Roche (2000), Centocor (today: Janssen, 2000), Schering (2001) and Pfizer (2003).

2006 A novel agent against alzheimer‘s

In 2006 Partner Roche starts clinical development of a HuCAL antibody against Alzheimer‘s disease (gantenerumab). Six years later, gantenerumab became the first MorphoSys antibody to enter late stage clinical development (phase 3). In 2018, new phase 3 trials where initiated to evaluate and approve gantenerumab in an optimized dosage regimen.

2008 Proprietary drug development

The first proprietary antibody MOR103 enters clinical development in 2008. In 2012, MorphoSys publishes positive study results with MOR103 in rheumatoid arthritis. The following year, MorphoSys signs a license agreement with GlaxoSmithKline for MOR103. In 2018, GlaxoSmith-Kline presents positive data from a phase 2 trial in rheumatoid arthritis patients.

2010 development of MOR208

In 2010, MorphoSys signs a license agreement with Xencor Inc. for MOR208. In the same year, MorphoSys starts clinical development of the antibody. The first positive data on MOR208 where presented in 2012. In 2017, the U.S. Food and Drug Administration awarded MOR208 breakthrough therapy designation in the blood cancer indication of diffuse large B cell lymphoma (DLBCL). MorphoSys intends to develop MOR208 toward regulatory approval as soon as possible.

2013 New partnerships for proprietary development

MorphoSys is increasingly entering into development and marketing partnerships with other biotech and pharmaceutical companies in order to advance its proprietary drug candidates. These include partnerships with GSK (2013 for MOR103), Merck (2014 for immunoncology), I-Mab Biopharma (2017 for MOR202 and 2018 for MOR210), Novartis (2018 for MOR106, together with Galapagos).

2017 first approval

In 2017, MorphoSys‘s licensing partner Janssen receives approval for Tremfya® (guselkumab) for the treatment of moderate to severe plaque psoriasis in the United States, Europe and Canada. Approvals in other countries to follow.

2018 Nasdaq ipo and establishment of us presence

With the listing and IPO at Nasdaq in 2018, MorphoSys gains numerous new investors and strengthens its capital base (gross proceeds USD 239 million). In addition, the US subsidiary MorphoSys US Inc. is established to prepare the Company‘s planned commercialization for MOR208 subject to FDA approval.

As a fully integrated biopharmaceutical company, we want to develop the medicine of tomorrow. Our interactive roadmap takes you on this path — click by click.

Start now
1992 The Beginning

Martinsried bei München.

The company was founded in Martinsried near Munich.

1999 First IPO

MorphoSys AG goes public on the Frankfurt Stock Exchange in 1999. On September 6, 2004, the Company entered into the TecDAX and in 2018 to the MDAX.

canvas
outlines
2000 Antibody Technology

In 2000, MorphoSys presented its HuCAL antibody library. This was followed by the HuCAL Gold antibody library (2001) and the HuCAL PLATINUM antibody library (2008). Ylanthia, the next generation of antibody technologies, was launched in 2011. Slonomics, which has been part of the MorphoSys technology portfolio since 2010, enables the precise optimization of antibodies from the Ylanthia library.

2004 Service and Discovery Partnerships

Initiation of a strategic partnership with Novartis in 2004, which expands into one of the largest antibody research collaborations in biotech and pharmaceuticals in 2007. MorphoSys has been researching and discovering antibodies on behalf of pharmaceutical partners since 1997. These include further partnerships with Bayer (1999), Roche (2000), Centocor (today: Janssen, 2000), Schering (2001) and Pfizer (2003).

canvas
outlines
 
canvas
outlines
2006 A Novel Agent Against Alzheimer‘s

In 2006 Partner Roche starts clinical development of a HuCAL antibody against Alzheimer‘s disease (gantenerumab). Six years later, gantenerumab became the first MorphoSys antibody to enter late stage clinical development (phase 3). In 2018, new phase 3 trials where initiated to evaluate and approve gantenerumab in an optimized dosage regimen.

2008 Proprietary Drug Development

The first proprietary antibody MOR103 enters clinical development in 2008. In 2012, MorphoSys publishes positive study results with MOR103 in rheumatoid arthritis. The following year, MorphoSys signs a license agreement with GlaxoSmithKline for MOR103. In 2018, GlaxoSmith-Kline presents positive data from a phase 2 trial in rheumatoid arthritis patients.

canvas
outlines
canvas
outlines Created with Sketch.
canvas_ie
2010 Development of MOR208

In 2010, MorphoSys signs a license agreement with Xencor Inc. for MOR208. In the same year, MorphoSys starts clinical development of the antibody. The first positive data on MOR208 where presented in 2012. In 2017, the U.S. Food and Drug Administration awarded MOR208 breakthrough therapy designation in the blood cancer indication of diffuse large B cell lymphoma (DLBCL). MorphoSys intends to develop MOR208 toward regulatory approval as soon as possible.

Previous Next
2013 New Partnerships for Proprietary Development

MorphoSys is increasingly entering into development and marketing partnerships with other biotech and pharmaceutical companies in order to advance its proprietary drug candidates. These include partnerships with GSK (2013 for MOR103), Merck (2014 for immunoncology), I-Mab Biopharma (2017 for MOR202 and 2018 for MOR210), Novartis (2018 for MOR106, together with Galapagos).

canvas
outlines
2017 First Approval

In 2017, MorphoSys‘s licensing partner Janssen receives approval for Tremfya® (guselkumab) for the treatment of moderate to severe plaque psoriasis in the United States, Europe and Canada. Approvals in other countries to follow.

2018 Nasdaq IPO and Establishment of U.S. Presence

With the listing and IPO at Nasdaq in 2018, MorphoSys gains numerous new investors and strengthens its capital base (gross proceeds USD 239 million). In addition, the US subsidiary MorphoSys US Inc. is established to prepare the Company‘s planned commercialization for MOR208 subject to FDA approval.

canvas
outlinesr

Our Goal: Is to develop MorphoSys into a Fully Integrated Biopharmaceutical Company.

Again
1 2 3 4 5 6 7 8 9 10